Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$83.07

0.64 (0.78%)

, INCY

Incyte

$119.76

-3.83 (-3.10%)

07:59
09/15/17
09/15
07:59
09/15/17
07:59

Morgan Stanley says baricitinib efficacy could be better if trial design changed

Morgan Stanley analyst David Risinger said Eli Lilly (LLY) and partner Incyte's (INCY) efficacy data from a Phase 2 study of baricitinib in atopic dermatitis looks inferior to competitors' "on the surface," but he contends that a steroid run-in period and usage during trial makes cross-trial comparison difficult. He thinks better efficacy is likely in Phase 3 if Lilly changes the trial design; however, if it does not, it could "end up being a commercial liability," Risinger tells investors. He keeps an Equal Weight rating and $86 price target on Eli Lilly shares.

LLY

Eli Lilly

$83.07

0.64 (0.78%)

INCY

Incyte

$119.76

-3.83 (-3.10%)

  • 18

    Oct

LLY Eli Lilly
$83.07

0.64 (0.78%)

08/31/17
PIPR
08/31/17
NO CHANGE
Target $103
PIPR
Overweight
Eli Lilly target raised to $103 on new baricitinib timeline at Piper Jaffray
Piper Jaffray analyst Richard Purkiss raised his price target for Eli Lilly (LLY) to $103 from $102 after the company and its partner Incyte (INCY) announced an updated regulatory timeline for baricitinib U.S. approval, its once-daily oral JAK inhibitor for rheumatoid arthritis. Lilly now expects to resubmit a new drug application before the end of January 2018, ahead of the analyst's prior expectation of year-end 2018. Purkiss now expects a launch in Q3 of 2018. The analyst reiterates an Overweight rating on Lilly shares.
08/31/17
LEER
08/31/17
NO CHANGE
LEER
Market Perform
Leerink remains cautious on Eli Lilly, Incyte baricitinib outlook
Leerink analyst Seamus Fernandez notes that Eli Lilly (LLY) and Incyte (INCY) announced that the New Drug Application for baricitinib will be resubmitted by the end of January 2018, following recent discussions with the FDA. Though the news comes as a positive surprise, the analyst remains cautious on his baricitinib outlook as it isstill unclear whether or not the new data will satisfy concerns raised by U.S. regulators in the April complete response letter citing dosing and safety issues. He reiterates a Market Perform rating on Eli Lilly's shares.
09/13/17
RHCO
09/13/17
NO CHANGE
RHCO
Eli Lilly Jardiance data positive, says SunTrust
SunTrust analyst John Boris says that data on the efficacy of Eli Lilly's Jardiance drug showed that it " reduces risk of cardiovascular death in type 2 diabetes patients irrespective of background blood glucose levels." The analyst thinks the data supports the use of the drug "in various (type 2 diabetes) settings." He expects the company's diabetes business to reach $10.5B in 2021, up from $4.4B in 2013. Boris keeps a $96 price target and a Buy rating on the shares.
09/15/17
JEFF
09/15/17
NO CHANGE
Target $96
JEFF
Buy
Eli Lilly price target raised to $96 from $89 at Jefferies
Jefferies analyst Jeffrey Holford raised his price target for Eli Lilly to $96 citing confidence in management's ability to deliver on margin commitments. Investors should not underappreciate Lilly's visibility on mid-single digit revenue growth paired with "significant operating leverage off a low margin base," Holford tells investors in a research note. He reiterates a Buy rating on the shares.
INCY Incyte
$119.76

-3.83 (-3.10%)

09/11/17
BMOC
09/11/17
NO CHANGE
BMOC
Incyte trial result 'assures commercial success,' says BMO Capital
BMO Capital analyst M. Ian Somaiya says the results of a trial of Incyte's (INCY) epacadostat, its selective IDO1 enzyme inhibitor, in combination with Merck's (MRK) Keytruda, in patients with advanced melanoma eliminates the risk of an upcoming Phase 3 trial of epacadostat and "assures its commercial success." The analyst adds, however, that "the bar continues to be raised for IO combinations," which may make it difficult for Incyte's stock to rise in the near-term. The analyst trimmed his price target on the shares to $163 from $172 to reflect the company's capital raise. But he keeps an Outperform rating on the stock.
09/11/17
09/11/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. MasterCard (MA) upgraded to Buy from Neutral at Guggenheim. 2. FireEye (FEYE) upgraded to Overweight from Equal Weight at Stephens with analyst Jonathan Ruykhaver saying he believes consensus expectations are modeling a decline in product revenue this year, though he thinks this is too low given the refresh opportunity from appliance sales about 3 years ago. 3. Teva (TEVA) upgraded to Buy from Neutral at BTIG with analyst Timothy Chiang saying the company's appointment of Kare Schultz as its new CEO is "a positive catalyst that should help create a floor for the shares and provide a boost to near-term investor sentiment." 4. Incyte (INCY) upgraded to Outperform from Market Perform at Raymond James with analyst Reni Benjamin citing increased confidence in the probability of success of the ongoing Phase III ECHO-301, Epa plus pembrolizumab study, the commercial prospects of the Epa franchise in melanoma and at least four other tumor types, as well as the U.S. commercial opportunity for baricitinib. 5. QuickLogic (QUIK) upgraded to Buy from Neutral at Roth Capital with analyst Suji Desilva saying he believes its revenues are better positioned for upside revisions. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/12/17
ARGS
09/12/17
NO CHANGE
ARGS
Incyte weakness creates buying opportunity, says Argus
Argus analyst Jasper Hellweg reports that Incyte's stock has fallen by 10% this month. The analyst remains upbeat on the company's growth outlook, citing what he sees as its "solid late-stage pipeline and key strategic R&D partnerships." He keeps a Buy rating on the stock.
09/14/17
RBCM
09/14/17
INITIATION
Target $136
RBCM
Sector Perform
Incyte initiated with a Sector Perform at RBC Capital
RBC Capital analyst Brian Abrahams started Incyte with a Sector Perform rating and $136 price target.

TODAY'S FREE FLY STORIES

OSTK

Overstock.com

$71.25

-4.4 (-5.82%)

10:45
01/19/18
01/19
10:45
01/19/18
10:45
Options
Overstock com call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$16.24

-0.535 (-3.19%)

10:35
01/19/18
01/19
10:35
01/19/18
10:35
Hot Stocks
Former GE vice chairman Wright says major issue is liabilities on balance sheet »

Speaking in a CNBC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

10:35
01/19/18
01/19
10:35
01/19/18
10:35
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

NINE

Nine Energy Services

10:31
01/19/18
01/19
10:31
01/19/18
10:31
Syndicate
Breaking Syndicate news story on Nine Energy Services »

Nine Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

10:30
01/19/18
01/19
10:30
01/19/18
10:30
General news
U.S. January consumer confidence slid 1.5 points to 94.4 »

U.S. January consumer…

PAYC

Paycom

$89.86

0.74 (0.83%)

, ALRM

Alarm.com

$39.43

1.16 (3.03%)

10:29
01/19/18
01/19
10:29
01/19/18
10:29
Conference/Events
Jefferies software analyst holds an analyst/industry conference call »

Software Analyst DiFucci…

PAYC

Paycom

$89.86

0.74 (0.83%)

ALRM

Alarm.com

$39.43

1.16 (3.03%)

CA

CA Technologies

$34.19

-0.28 (-0.81%)

RHT

Red Hat

$125.41

-0.06 (-0.05%)

ORCL

Oracle

$50.43

0.2 (0.40%)

SSNC

SS&C

$49.94

0.23 (0.46%)

VMW

VMware

$136.19

0.56 (0.41%)

CTXS

Citrix

$91.38

0.19 (0.21%)

MSFT

Microsoft

$90.10

-0.04 (-0.04%)

SYMC

Symantec

$27.25

-0.27 (-0.98%)

PANW

Palo Alto Networks

$157.60

-0.22 (-0.14%)

APTI

Apptio

$24.23

0.23 (0.96%)

CHKP

Check Point

$103.20

-0.37 (-0.36%)

NICE

Nice

$93.83

1.2 (1.30%)

SPLK

Splunk

$91.43

0.86 (0.95%)

RNG

RingCentral

$53.55

0.35 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 23

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 05

    Feb

  • 06

    Feb

  • 06

    Feb

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 12

    Feb

  • 26

    Feb

  • 27

    Feb

10:25
01/19/18
01/19
10:25
01/19/18
10:25
General news
The Michigan sentiment drop to a 6-month low of 94.4 »

The Michigan sentiment…

URG

UR-Energy

$0.72

-0.0279 (-3.72%)

10:25
01/19/18
01/19
10:25
01/19/18
10:25
Conference/Events
UR-Energy to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

AMZN

Amazon.com

$1,293.32

-1.68 (-0.13%)

10:25
01/19/18
01/19
10:25
01/19/18
10:25
Conference/Events
Leerink healthcare analysts hold an analyst/industry conference call »

Healthcare Analysts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 01

    Feb

  • 18

    Mar

BDX

Becton Dickinson

$233.54

1.42 (0.61%)

, ATHN

athenahealth

$125.53

-0.65 (-0.52%)

10:24
01/19/18
01/19
10:24
01/19/18
10:24
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

BDX

Becton Dickinson

$233.54

1.42 (0.61%)

ATHN

athenahealth

$125.53

-0.65 (-0.52%)

CRBP

Corbus Pharmaceuticals

$7.95

-0.25 (-3.05%)

TTD

Trade Desk

$48.36

-1.12 (-2.26%)

IPCI

Intellipharmaceutics

$0.80

-0.02 (-2.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 02

    Feb

  • 06

    Feb

Z

Zillow

$43.97

-0.57 (-1.28%)

, ZG

Zillow

$43.86

-0.49 (-1.10%)

10:24
01/19/18
01/19
10:24
01/19/18
10:24
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

Z

Zillow

$43.97

-0.57 (-1.28%)

ZG

Zillow

$43.86

-0.49 (-1.10%)

BLMN

Bloomin' Brands

$21.96

0.02 (0.09%)

PH

Parker-Hannifin

$210.94

0.4 (0.19%)

MKC

McCormick

$100.10

-2.81 (-2.73%)

WNS

WNS Holdings

$44.30

-0.98 (-2.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 26

    Feb

NKE

Nike

$66.12

2.0086 (3.13%)

, ANF

Abercrombie & Fitch

$19.45

0.5 (2.64%)

10:24
01/19/18
01/19
10:24
01/19/18
10:24
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

NKE

Nike

$66.12

2.0086 (3.13%)

ANF

Abercrombie & Fitch

$19.45

0.5 (2.64%)

CMG

Chipotle

$338.74

1.21 (0.36%)

FL

Foot Locker

$49.49

0.8999 (1.85%)

PM

Philip Morris

$107.12

2.05 (1.95%)

MO

Altria Group

$71.38

1.35 (1.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 01

    Feb

  • 06

    Feb

ADT

ADT Inc.

, APO

Apollo Global

$34.07

-1.005 (-2.87%)

10:22
01/19/18
01/19
10:22
01/19/18
10:22
Syndicate
Breaking Syndicate news story on ADT Inc., Apollo Global »

ADT Inc. opens at $12.65,…

ADT

ADT Inc.

APO

Apollo Global

$34.07

-1.005 (-2.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 19

    Jan

NSPR

InspireMD

$0.17

-0.0019 (-1.11%)

10:21
01/19/18
01/19
10:21
01/19/18
10:21
Hot Stocks
InspireMD reports independent publication highlighting advantages of CGuard EPS »

InspireMD announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ODP

Office Depot

$3.51

0.01 (0.29%)

10:20
01/19/18
01/19
10:20
01/19/18
10:20
Options
Defensive option play in Office Depot »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:20
01/19/18
01/19
10:20
01/19/18
10:20
General news
Treasury Action: yields paused at highs after surging »

Treasury Action: yields…

10:18
01/19/18
01/19
10:18
01/19/18
10:18
Conference/Events
RBC Capital technology analysts hold an analyst/industry conference call »

Technology Analysts…

$NSD

NASDAQ Market Internals

10:17
01/19/18
01/19
10:17
01/19/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

10:16
01/19/18
01/19
10:16
01/19/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
01/19/18
01/19
10:15
01/19/18
10:15
General news
FX Action: The dollar »

FX Action: The dollar…

FAZ

Direxion Financial Bear 3x

$10.45

-0.1438 (-1.36%)

10:10
01/19/18
01/19
10:10
01/19/18
10:10
Options
Direxion Daily Financial Bear 3X Shares draws a notable option block »

Direxion Daily Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NINE

Nine Energy Services

10:09
01/19/18
01/19
10:09
01/19/18
10:09
Syndicate
Breaking Syndicate news story on Nine Energy Services »

Nine Energy Services IPO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

COLD

Americold Realty Trust

10:09
01/19/18
01/19
10:09
01/19/18
10:09
Syndicate
Breaking Syndicate news story on Americold Realty Trust »

Americold Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

QRVO

Qorvo

$68.76

-1.92 (-2.72%)

10:05
01/19/18
01/19
10:05
01/19/18
10:05
Technical Analysis
Technical Take: Qorvo drops, levels to watch »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:04
01/19/18
01/19
10:04
01/19/18
10:04
General news
Potential government shutdown not doing much to rattle market »

Stock futures were a bit…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.